- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07465172
GDF-15 und sein Zusammenhang mit behandlungsbedingten unerwünschten Ereignissen bei Brustkrebs (GRADE)
Eine multizentrische, prospektive Kohortenstudie zur Untersuchung des Zusammenhangs zwischen Veränderungen der GDF-15-Spiegel und behandlungsbedingten Nebenwirkungen während der T-DXd-Behandlung bei Brustkrebspatientinnen.
GRADE is trying to find out if there is a link between a hormone called GDF-15 and the side effects that people can experience when taking T-DXd.
GDF-15 can be measured in the blood. GDF-15 levels in the blood will go up when the body is stressed under certain conditions, including breast cancer. There is a link between high GDF-15 levels and the nausea and vomiting experienced with "morning sickness" in pregnancy. It has also been shown that GDF-15 levels will go up with the use of other types of chemotherapy that are known to cause nausea and vomiting.
Side effects such as feeling sick (nausea), vomiting and weight loss are common with T-DXd. Sometimes, these can be so severe that treatment needs to be stopped early. The investigators can't predict who will get bad side effects and who will not.
If the investigators can find out if there is a link between GDF-15 and the side effects of T-DXd, they can use this information in future clinical trials.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Growth differentiation factor 15 (GDF-15), a stress-related hormone also known as macrophage inhibitory cytokine-1 (MIC-1), is a member of the transforming growth factor-beta (TGF-β) superfamily. It is not expressed under basal conditions but can be released in response to pro-inflammatory conditions such as obesity, insulin resistance, renal and heart failure, and malignancy.
Pre-clinical studies have established the role of elevated GDF-15 levels in tumour and platinum-based chemotherapy induced emesis and cachexia. It has also been proposed as a biomarker for all-cause mortality, as well as for poor prognoses in patients with cancer.
The hypothesis is that there is a positive correlation between increased levels of GDF-15 and the severity of treatment-related adverse events (particularly nausea, vomiting and cachexia) experienced by patients with breast cancer receiving T-DXd.
The aim of the study is to explore the relationship between relative change in levels of GDF-15 from baseline (pre-treatment) to after receiving T-DXd (post-C2 and at end of treatment) and the severity of treatment-related adverse events experienced by patients with breast cancer receiving T-DXd.
If a positive relationship is found with any or all of these objectives, then monoclonal antibodies inhibiting GDF-15 (such as ponsegromab or visugromab) may present a promising therapeutic and supportive option for patients receiving T-DXd.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Tracey Hay
- Telefonnummer: +61 (0) 2 4925 5277
- E-Mail: tracey.hay@bctrials.org.au
Studieren Sie die Kontaktsicherung
- Name: Michelle Li, Dr
- Telefonnummer: +61 (0) 3 8559 5935
- E-Mail: michelle.li@petermac.org
Studienorte
-
-
New South Wales
-
Newcastle, New South Wales, Australien, 2290
- Lake Macquarie Private Hospital
-
Kontakt:
- Nick Zdenkowski, Dr
- Telefonnummer: +61 (02) 4942-2600
- E-Mail: nick.zdenkowski@newcastle.edu.au
-
Hauptermittler:
- Nick Zdenkowski, Dr
-
-
Victoria
-
Melbourne, Victoria, Australien, 3000
- Peter MacCallum Cancer Centre
-
Kontakt:
- Sherene Loi, Prof
- Telefonnummer: +61 (03) 8559-5935
- E-Mail: sherene.loi@petermac.org
-
Hauptermittler:
- Sherene Loi, Prof
-
-
-
-
-
Okayama, Japan, 700-8558
- Okayama University Hospital
-
Kontakt:
- Tadahiko Shien, Prof
- Telefonnummer: +81 (08) 62357265
- E-Mail: tshien@md.okayam-u.ac.jp
-
Hauptermittler:
- Tadahiko Shien, Prof
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Dana-Farber Cancer Institute
-
Kontakt:
- Michelle Li, Dr
- Telefonnummer: +61 (0) 3 8559 5935
- E-Mail: michelle.li@petermac.org
-
Hauptermittler:
- Michelle Li, Dr
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Participants aged ≥18 years.
- Histologically confirmed diagnosis of metastatic/advanced unresectable HER2-positive or HER2-low breast cancer.
- Planned to start treatment with T-DXd.
- Life expectancy of at least 4 months.
Exclusion Criteria:
- Current active reversible causes of decreased food intake, as determined by the Investigator.
- Receiving tube feedings or any kind of parenteral nutrition at the time of enrolment into the study.
- Ongoing cachexia attributable to other reasons unrelated to cancer or cancer treatment as determined by the Investigator that may confound interpretation of weight loss due to T-DXd.
- Current adherence to a calorie-restricted diet with the intention of weight loss.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Sonstiges: Blood Collection for GDF-15
Blood collection for GDF-15 during T-DXd treatment. |
Blood samples of 20-30mL (approximately 1-2 tablespoons in total) will be taken 4 times:
At each blood collection, participants will be asked about:
Personal and health information will also be collected from participants:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Nausea prior to Cycle 3 of T-DXd, graded according to Common Terminology Criteria for Adverse Advents (CTCAE) v5.0.
Zeitfenster: From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
To investigate if the percentage change in levels of GDF-15 from baseline to after receiving 2 cycles of T-DXd is associated with moderate/high grade nausea (CTCAE Grade 2-4) experienced at this timepoint by patients with metastatic/advanced unresectable HER2-positive or HER2-low breast cancer. |
From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Vomiting prior to Cycle 3 of T-DXd, graded as per CTCAE v5.0.
Zeitfenster: From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
To investigate if the percentage change in levels of GDF-15 from baseline to after receiving 2 cycles of T-DXd is associated with moderate/high grade vomiting (CTCAE Grade 2-4) experienced by patients at this timepoint. |
From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
|
Weight loss (cachexia) prior to Cycle 3 of T-DXd, graded as per CTCAE v5.0.
Zeitfenster: From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
To investigate if the percentage change in levels of GDF-15 from baseline to after receiving 2 cycles of T-DXd is associated with moderate/high grade cachexia (CTCAE Grade 2-4) experienced by patients at this timepoint. |
From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
|
Percentage change in GDF-15 and its correlation with treatment-related adverse events (TRAEs)
Zeitfenster: From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
To explore the correlation of the percentage change in levels of GDF-15 with the treatment-related adverse events (CTCAE Grade 2-4). Treatment-related adverse events (TRAEs) are adverse events classified as possibly, probably or definitely related to T-DXd treatment. TRAEs will be graded as per CTCAE v5.0. |
From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
|
Progression-free survival (PFS)
Zeitfenster: Time from treatment start with T-DXd to the first occurrence of disease progression or death due to any cause, whichever came first, assessed up to 6 months.
|
To explore the relationship between baseline levels of GDF-15 and progression-free survival (PFS) on T-DXd |
Time from treatment start with T-DXd to the first occurrence of disease progression or death due to any cause, whichever came first, assessed up to 6 months.
|
|
Time to treatment failure (TTF)
Zeitfenster: Time from treatment start with T-DXd to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death, whichever came first, assessed up to 6 months.
|
To explore the relationship between baseline levels of GDF-15 and time to treatment failure (TTF) on T-DXd. |
Time from treatment start with T-DXd to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death, whichever came first, assessed up to 6 months.
|
|
HER2 copy number
Zeitfenster: Prior to treatment commencement.
|
To explore the relationship between HER2 copy number and change in levels of GDF-15. HER2 copy number determined by in-situ hybridization (ISH) on most recent available histopathology specimen or tumour/plasma genomic data (DNA/RNA), preferably in the metastatic setting |
Prior to treatment commencement.
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Exploratory: Association of baseline levels of GDF-15 with Treatment Related Adverse Events (TRAEs).
Zeitfenster: TRAEs occurring after Cycle 2, after Cycle 3 and within 30 days of end of treatment with T-DXd (each cycle is 28 days).
|
To explore if baseline levels of GDF-15 are associated with the incidence and severity of TRAEs experienced by patients on T-DXd, graded as per CTCAE v5.0. |
TRAEs occurring after Cycle 2, after Cycle 3 and within 30 days of end of treatment with T-DXd (each cycle is 28 days).
|
|
Exploratory: Longitudinal change in weight after 2 cycles of T-DXd
Zeitfenster: After receiving 2 cycles of T-DXd (each cycle is 28 days).
|
To explore if the longitudinal change in levels of GDF-15 from baseline to after receiving 2 cycles of T-DXd is associated with trends in weight change. Weight change is measured as a percentage of baseline weight. End-of-treatment is defined as cessation of treatment due to disease progression or treatment toxicity. |
After receiving 2 cycles of T-DXd (each cycle is 28 days).
|
|
Exploratory: Longitudinal change in weight at end-of-treatment
Zeitfenster: At end-of-treatment with T-DXd; end-of-treatment is defined as cessation of treatment due to disease progression or treatment toxicity, whichever came first, assessed up to 6 months.
|
To explore if the longitudinal change in levels of GDF-15 from baseline at end-of-treatment with T-DXd is associated with trends in weight change. Weight change is measured as a percentage of baseline weight. |
At end-of-treatment with T-DXd; end-of-treatment is defined as cessation of treatment due to disease progression or treatment toxicity, whichever came first, assessed up to 6 months.
|
Mitarbeiter und Ermittler
Ermittler
- Studienleiter: Heath Badger, Breast Cancer Trials, Australia and New Zealand
- Studienstuhl: Sherene Loi, Prof, Peter MacCallum Cancer Centre, Australia
- Studienstuhl: Michelle Li, Dr, Peter MacCallum Cancer Centre, Australia
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach Standort
- Neubildungen
- Körpergewicht
- Anzeichen und Symptome, Verdauungstrakt
- Änderungen des Körpergewichts
- Hautkrankheiten
- Brusterkrankungen
- Pathologische Zustände, Anzeichen und Symptome
- Haut- und Bindegewebserkrankungen
- Anzeichen und Symptome
- Gewichtsverlust
- Neoplasien der Brust
- Brechreiz
- Erbrechen
- Peptide
- Aminosäuren, Peptide und Proteine
- Proteine
- Biologische Faktoren
- Interzelluläre Signalpeptide und Proteine
- Zytokine
- Wachstums- und Differenzierungsfaktoren
- TGF-beta-Superfamilie-Proteine
- Wachstumsdifferenzierungsfaktor 15
Andere Studien-ID-Nummern
- BCT 2502
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Anonymised Individual Patient Data (IPD) collected during the trial.
IPD-Sharing-Zeitrahmen
Data will be made available for request after publication of the main/final study results; no end date.
IPD-Sharing-Zugriffskriterien
Researchers who submit a research proposal and BCT Data Request Application, which is assessed by BCT to have appropriate scientific value. Applications will be subject to approval by Breast Cancer Trials concept@bctrials.org.au (refer to BCT Data Sharing Guidelines).
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- ANALYTIC_CODE
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .